The objective of the project was to examine the effects of CBD on canine cancer cell growth proliferation with aims towards understanding the signaling pathways involved and the apoptotic response related to CBD. A second aim was to understand the influence of CBD co-treatment with chemotherapeutics such as doxorubicin and vincristine. Continue reading “Research Update CHF 02643-A Final: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity”
Research Update CHF 02692-A Final: Diagnostic Accuracy of Point of Care Analysis of Canine Urine and Plasma in Marijuana Toxicosis
Between February 2019 and March 2020, 56 dogs were enrolled in the study. The amount of Δ9- tetrohydrocannabinol (THC) ingested was available for eight dogs (14%). The average dose ingested for those dogs was 175 mg (range 35-4,400). Types of sources reported included both commercial and homemade edible products (15), marijuana plant material (3), and commercial THC concentrate (1). Continue reading “Research Update CHF 02692-A Final: Diagnostic Accuracy of Point of Care Analysis of Canine Urine and Plasma in Marijuana Toxicosis”
Research Update CHF 02323 Final: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy
The preparations for the CBD epilepsy study were started in December 2017, including hiring a full-time research assistant and part-time work/study student, creating all of the study documents necessary for the trial, and creating a newsletter/announcement for Colorado veterinarians. We began enrolling patients for the study at the end of January 2018. We anticipated enrolling 20 patients per year; we have completed the anticipated enrollment of 60 dogs. Additionally, we have been working with outside clinics in Colorado to help us in the enrollment process of the study. Three local specialty clinics with board-certified neurologists are conducting the study with CSU’s oversight at their hospitals and general veterinarians are helping with the recheck appointments and blood draws. Continue reading “Research Update CHF 02323 Final: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy”
Research Update CHF 02692-A EY1: Diagnostic Accuracy of Point of Care Analysis of Canine Urine and Plasma in Marijuana Toxicosis
Samples obtained from a total of 56 dogs with either confirmed or suspected exposure to Δ9- tetrahydrocannabidiol (Δ9-THC) have been analyzed by both point of care and liquid chromatography/tandem mass spectrometry (LC/MS-MS). Of those enrolled, 55 (98%) were confirmed positive for Δ9-THC by LC/MS-MS on plasma samples. Of the 56 urine samples tested, 17 tested positive using the Alere drug screen iCassette for THC, and 26 tested positive using the NarcoCheck THC Predosage test. Continue reading “Research Update CHF 02692-A EY1: Diagnostic Accuracy of Point of Care Analysis of Canine Urine and Plasma in Marijuana Toxicosis”
Research Update CHF 02643-A MY2: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity
We have completed a lot of the proposed work related to the effects of CBD on cell death and autophagy and the upregulation of the MAP kinase pathway which appears to be involved, however the main mechanism of apoptosis has not been elucidated which may just be directly related to the autophagy induction. Continue reading “Research Update CHF 02643-A MY2: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity”
Research Update CHF 02323 EY-3: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy
The preparations for the CBD epilepsy study were started in December 2017, including hiring a full[1]time research assistant and part-time work/study student, creating all of the study documents necessary for the trial, and creating a newsletter/announcement for Colorado veterinarians. We began enrolling patients for the study at the end of January 2018. Continue reading “Research Update CHF 02323 EY-3: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy”
Research Update Mid-year 3 CHF 02323: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy
The preparations for the CBD epilepsy study were started in December 2018, including hiring a fulltime research assistant and part-time work/study student, creating all of the study documents necessary for the trial, and creating a newsletter/announcement for Colorado veterinarians. We began enrolling patients for the study at the end of January 2018. We anticipated enrolling 20 patients per year; therefore, we are on track with 54 patients in 2 1/2 years.
Research Update Mid- and End-yr 1 CHF 02643-A: Examination of the Effects of Cannabidiol on Canine Neoplastic Cell Apoptosis/Autophagy and Potential for Chemotherapy Resistance or Sensitivity
Initial studies on cytotoxicity by the research team show that CBD has cytotoxic activity on a variety of canine cancer cell lines at modest concentrations in the laboratory. These effects cause apoptosis, or programmed cell death, within a very short time frame, suggesting a discrete mechanism.
Research Update Mid-year 2 CHF 02323: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy
Research Update from Dr. Stephanie McGrath looking at use of CBD for the treatment of epilepsy.
